ArticleDEN open2026
Risk Factors for Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis in Patients With Post-Endoscopic Sphincterotomy Papillae.
Article in DEN open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is a well-known complication. While most reported risk factors relate to treatment-naïve papillae, those in patients with post-endoscopic sphincterotomy (post-EST) papillae remain unclear. We aimed to identify risk factors for PEP in patients with a history of EST undergoing ERCP for biliary disease. Methods: We retrospectively analyzed 678 patients with prior EST who underwent ERCP between January 2017 and October 2023. PEP was diagnosed according to established criteria. Logistic regression analyses were performed to identify risk factors. To account for repeated ERCP sessions, additional analyses using cluster-robust standard errors were conducted. Body mass index (BMI) was evaluated as both a continuous variable and according to World Health Organization categories. Prophylactic rectal diclofenac or intravenous nafamostat mesilate was administered at the operator's discretion. Results: The mean age was 75.4 years, and PEP occurred in 4.4%. Multivariate analysis identified female sex ( Conclusions: Low BMI is a consistent risk factor for PEP in patients with post-EST papillae. The effectiveness of pharmacologic prophylaxis may differ from that in treatment-naïve papillae and warrants prospective evaluation. Trial Registration: N/A.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.